Last updated: September 5, 2026
Sodium fluoride and triclosan were combined in prescription-style and consumer oral-care products, most prominently Colgate-Palmolive’s Colgate Total toothpaste in the United States. Sodium fluoride provided anticaries protection, while triclosan provided antibacterial and antigingivitis activity. The combination’s U.S. regulatory position was tied to an approved new drug application rather than a conventional generic-market structure. Its commercial trajectory weakened as triclosan faced regulatory scrutiny, consumer resistance, environmental concerns, and replacement by stannous fluoride formulations.
The product class has limited current patent value. The principal commercial barriers are formulation know-how, brand equity, regulatory dossiers, manufacturing controls, and consumer distribution rather than unexpired composition patents. No biosimilar pathway applies.
What drug product contains sodium fluoride and triclosan?
The best-known product was Colgate Total, manufactured by Colgate-Palmolive. The historical U.S. formulation used approximately 0.3% triclosan and 0.24% sodium fluoride, with triclosan providing antibacterial activity and sodium fluoride providing cavity prevention.
| Attribute |
Historical sodium fluoride-triclosan product |
| Active ingredients |
Sodium fluoride and triclosan |
| Principal brand |
Colgate Total |
| Sponsor |
Colgate-Palmolive Company |
| Dosage form |
Dentifrice, typically toothpaste |
| Primary indications |
Anticaries protection and gingivitis control |
| U.S. regulatory route |
NDA approval |
| Generic pathway |
ANDA or OTC pathway depended on the formulation and regulatory status |
| Biosimilar relevance |
None |
| Principal commercial markets |
United States, Europe, Latin America, Asia, and other international markets |
The combination was commercially differentiated because it addressed both caries and plaque or gingivitis in one daily-use product. Sodium fluoride was already a well-established anticaries active. Triclosan supplied the product’s antibacterial positioning but also created the principal regulatory and reputational exposure.
What is the FDA regulatory status of sodium fluoride and triclosan?
The historical U.S. Colgate Total formulation received FDA approval through an NDA. The FDA approved Colgate Total in 1997 for use in reducing plaque and gingivitis and preventing cavities. The product was unusual because the triclosan indication was supported through an NDA rather than relying only on the anticaries OTC monograph.
Sodium fluoride is recognized under the FDA’s anticaries monograph framework. The FDA’s anticaries monograph permits specified fluoride actives, concentrations, and labeling conditions for OTC dentifrices. Triclosan does not have an equivalent broad OTC oral-care monograph status that would automatically authorize the historical combination.
The principal FDA milestones were:
| Date |
Event |
| 1997 |
FDA approval of Colgate Total containing triclosan and sodium fluoride |
| 2000s |
Continued U.S. marketing under NDA-based labeling |
| 2016 |
FDA removed triclosan from the final monograph for consumer antiseptic wash products because sponsors had not established long-term safety and effectiveness for those uses |
| 2019 |
FDA approved a new Colgate Total formulation using stannous fluoride rather than triclosan |
| 2020s |
U.S. Colgate Total products were marketed with stannous fluoride, not the historical triclosan formulation |
The 2016 FDA action concerned consumer antiseptic washes, not a direct withdrawal of every triclosan-containing dental product. Its commercial effect was broader than the formal scope of the rule because it increased regulatory and consumer pressure on triclosan across personal-care categories. The FDA’s 2019 approval of a stannous fluoride Colgate Total formulation provided a commercially viable replacement.
What patents protected sodium fluoride and triclosan formulations?
The historical patent estate covered more than the two active ingredients. Key patent themes included:
- Triclosan-containing dentifrice compositions.
- Copolymers used to retain triclosan on oral surfaces.
- Compatibility between triclosan and fluoride salts.
- Flavor, foaming, abrasivity, and stability systems.
- Methods for reducing plaque, gingivitis, and oral bacteria.
- Manufacturing processes for dispersing triclosan uniformly in toothpaste.
A commercially important formulation typically required a combination of triclosan, a fluoride source, an abrasive system, a surfactant, a humectant, a flavor system, and a polymer or delivery aid. Patent protection around those combinations was more relevant than a basic patent on sodium fluoride or triclosan individually.
The original U.S. patents associated with early triclosan dentifrice technology generally had filing dates in the 1980s and 1990s. Those patents have reached their statutory expiration periods. Patent-term adjustment could have shifted individual expiration dates by limited periods, but it did not preserve a broad, current U.S. monopoly over the sodium fluoride-triclosan combination.
How strong is the current patent estate?
The current patent estate is weak for the historical combination.
| Patent category |
Current commercial strength |
| Sodium fluoride composition patents |
Low; active ingredient is long established |
| Triclosan composition patents |
Low for basic use; most early rights expired |
| Triclosan-fluoride dentifrice claims |
Low to moderate only where narrow claims survive |
| Delivery-polymer claims |
Potentially relevant in selected jurisdictions, but generally aged |
| Manufacturing know-how |
Moderate; remains difficult to replicate perfectly but is not a statutory exclusivity right |
| Brand and trade dress |
Stronger than active-ingredient patent protection |
| Regulatory dossier |
Relevant for NDA-based products, but not equivalent to a modern biologic exclusivity period |
The commercial risk for a new entrant would therefore come from formulation performance, regulatory compliance, trademark restrictions, and market acceptance. Patent infringement risk from the original active-ingredient combination is materially lower than it was during the product’s launch period.
When does sodium fluoride and triclosan lose exclusivity?
The combination’s effective U.S. exclusivity ended through a combination of patent expiry, regulatory substitution, and product reformulation rather than through one single cliff date.
The historical exclusivity timeline is:
| Period |
Exclusivity position |
| 1990s |
NDA and formulation patents created meaningful entry barriers |
| Early 2000s |
Colgate Total had strong brand and formulation differentiation |
| Mid-to-late 2010s |
Early patent rights had largely expired or approached expiration |
| 2016 onward |
Triclosan regulatory scrutiny weakened the product’s strategic position |
| 2019 |
Stannous fluoride replacement reduced the commercial relevance of the old formulation |
| Current period |
No major U.S. exclusivity barrier protects the historical combination |
The FDA’s five-year new chemical entity exclusivity does not appear to be the principal commercial story for this product because the ingredients were not new molecular entities in the modern NDA sense. The product’s value came from the approved combination, formulation development, clinical evidence, and brand execution.
What is the Orange Book status of the product?
Colgate Total’s historical U.S. NDA was listed in FDA drug databases and associated with the product’s approved regulatory status. Orange Book significance was more limited than for a conventional small-molecule prescription product because toothpaste substitution does not operate like automatic pharmacy substitution under an ANDA.
The relevant distinctions are:
- Sodium fluoride toothpaste can qualify under the OTC anticaries framework when it meets monograph conditions.
- A triclosan-containing product with plaque and gingivitis claims relied on a more specific regulatory basis.
- An applicant seeking to commercialize an equivalent product would need to address formulation, labeling, manufacturing, and regulatory pathway issues.
- A Paragraph IV certification would be relevant only if an ANDA applicant sought approval against listed patents associated with an NDA.
- Patent expiry and product reformulation reduced the practical importance of Paragraph IV litigation.
No material current Paragraph IV campaign is associated with the historical sodium fluoride-triclosan toothpaste combination. The market has moved toward other fluoride systems rather than toward a large-scale generic challenge to the legacy formulation.
Which companies challenged or replaced triclosan toothpaste?
The principal competitive pressure came from product substitution, not patent litigation.
Stannous fluoride competitors
Stannous fluoride became the leading technical replacement in premium anticaries and gingivitis toothpaste. Procter & Gamble marketed Crest formulations using stannous fluoride, while Colgate-Palmolive introduced a stannous fluoride version of Colgate Total in the United States.
Sodium fluoride competitors
Sodium fluoride remains widely used in mass-market toothpaste. Major competitors include:
- Procter & Gamble, through Crest and related brands.
- Haleon, through Sensodyne and other oral-care products.
- Church & Dwight, through Arm & Hammer and related products.
- Unilever, through Signal, Pepsodent, and other regional brands.
- Private-label manufacturers serving retailers and pharmacy chains.
The competitive distinction is no longer primarily sodium fluoride versus triclosan. It is more often:
| Product platform |
Main positioning |
| Sodium fluoride |
Basic cavity protection, broad mass-market use |
| Stannous fluoride |
Cavity protection, gingivitis, sensitivity, and surface-stain claims |
| Sodium monofluorophosphate |
Regional and value-oriented fluoride platform |
| Hydroxyapatite |
Non-fluoride or alternative remineralization positioning in selected markets |
| Triclosan combinations |
Legacy antibacterial platform with regulatory and consumer constraints |
What formulation patents remain commercially relevant?
The most relevant formulation barriers are likely to involve newer or redesigned systems rather than the historical triclosan-sodium fluoride combination.
Potentially important claim categories include:
- Low-water or anhydrous toothpaste bases.
- Stabilized stannous fluoride systems.
- Polymers that improve active retention on teeth.
- Abrasive systems that control staining and enamel wear.
- Desensitizing and whitening combinations.
- Flavor systems compatible with metal fluoride actives.
- Tube and dispensing technologies.
- Manufacturing methods that improve active uniformity and shelf stability.
A company attempting to reintroduce a sodium fluoride-triclosan toothpaste would face a lower basic patent risk than a company developing a modern stannous fluoride platform. The main technical challenge would be formulation performance and regulatory acceptance, not ownership of sodium fluoride or triclosan.
What patent litigation and settlement agreements affect the combination?
There is no prominent current U.S. patent litigation campaign centered on sodium fluoride-triclosan toothpaste. The historical product’s disputes, if any, were more likely to concern formulation patents, trademarks, advertising claims, or competition between oral-care brands than a sustained ANDA litigation program.
There is no material public settlement structure comparable to those seen in high-value prescription drug markets. No major revenue-sharing or authorized-generic arrangement is central to the current commercial position of the combination.
What is the financial trajectory of the sodium fluoride-triclosan market?
The historical combination experienced a decline in strategic value even though oral care remained a large and durable consumer-health market.
Revenue drivers
The product’s original revenue profile was supported by:
- Premium pricing for combined cavity and gingivitis protection.
- Global distribution through Colgate’s retail network.
- High repeat purchase rates for toothpaste.
- Strong brand recognition.
- Regulatory differentiation from ordinary fluoride toothpaste.
Revenue pressures
The principal pressures were:
- Triclosan safety and environmental controversy.
- Consumer movement away from antimicrobial chemicals.
- Regulatory restrictions in some jurisdictions.
- Reformulation costs.
- Substitution by stannous fluoride.
- Private-label competition.
- Limited ability to sustain premium pricing after the differentiation weakened.
Colgate-Palmolive reports oral-care performance at business-segment and category levels rather than isolating revenue from the historical sodium fluoride-triclosan formulation. The company’s public financial reporting therefore does not establish a product-specific revenue series for legacy Colgate Total triclosan toothpaste.
The financial trajectory can be summarized as follows:
| Phase |
Market economics |
| Launch and expansion |
Premium product with strong differentiation |
| Maturity |
High brand retention and broad geographic distribution |
| Regulatory pressure |
Rising reformulation and compliance costs |
| Replacement period |
Migration toward stannous fluoride |
| Current position |
Legacy formulation has limited standalone value |
The oral-care category remains financially attractive, but that category growth should not be attributed to the legacy triclosan formulation. Current growth is more likely to accrue to products positioned around sensitivity, whitening, enamel protection, gum health, and stannous fluoride technology.
What generic launch risks exist?
A generic or private-label launch would face moderate operational risk but limited basic patent risk.
| Risk |
Assessment |
| Basic active-ingredient patent risk |
Low |
| Formulation patent risk |
Low to moderate, depending on claims |
| FDA pathway risk |
Moderate for antibacterial and gingivitis claims |
| Manufacturing risk |
Moderate |
| Clinical substantiation risk |
Moderate to high for differentiated therapeutic claims |
| Brand competition |
High |
| Consumer acceptance of triclosan |
Weak |
| Supply-chain risk |
Moderate |
| International regulatory risk |
High because rules differ by jurisdiction |
A company could manufacture a fluoride toothpaste without triclosan under established OTC conditions more easily than it could reproduce the historical combination with equivalent antibacterial claims. The triclosan component creates the greater regulatory burden and the weaker commercial proposition.
What is the geographic coverage of the product and its IP?
Triclosan toothpaste was marketed internationally, but regulatory treatment varied by country.
- The United States permitted the historical product under its NDA framework before the later shift to stannous fluoride.
- The European Union applied greater scrutiny to triclosan concentrations and cosmetic use.
- Some Asian and Latin American markets continued to permit triclosan-containing oral-care products under local rules.
- Patent protection varied by national filing, grant, maintenance, and expiration status.
- Product availability depended more on local regulatory acceptance and brand strategy than on one global patent.
The geographic IP position is therefore fragmented. Any current commercial assessment must distinguish U.S. NDA status, European cosmetic or medicinal-product rules, and national patent expiration dates.
How does sodium fluoride-triclosan compare with sodium fluoride-stannous fluoride products?
| Factor |
Sodium fluoride-triclosan |
Sodium fluoride or stannous fluoride replacement |
| Historical differentiation |
Strong antibacterial positioning |
Broad cavity, sensitivity, and gum-health positioning |
| Regulatory outlook |
Constrained |
More commercially favorable |
| Consumer perception |
Weakened |
Stronger |
| Patent value |
Mostly expired legacy rights |
More active modern formulation estates |
| Manufacturing complexity |
Requires triclosan compatibility and uniformity |
Stannous stabilization is technically demanding |
| Growth potential |
Limited |
Higher in premium oral care |
| Current brand relevance |
Mainly historical |
Current market focus |
Key Takeaways
- Sodium fluoride-triclosan was a historically important oral-care combination, especially in Colgate Total.
- Sodium fluoride supplied anticaries protection; triclosan supplied antibacterial and antigingivitis activity.
- The U.S. product was supported by an NDA rather than a simple OTC monograph position.
- Basic patent protection is largely exhausted or commercially weak.
- No major current Paragraph IV or biosimilar risk defines the market.
- Triclosan’s regulatory and consumer problems drove substitution by stannous fluoride.
- Product-specific revenue is not separately disclosed by Colgate-Palmolive.
- Current value lies in oral-care brands, distribution, formulation know-how, and newer fluoride systems rather than in the legacy combination.
- A generic launch would face limited basic patent risk but meaningful regulatory, formulation, and commercial barriers.
FAQs
Is triclosan still used in toothpaste?
Triclosan has been reduced or removed from many major-market toothpaste formulations. Its continued use depends on country-specific regulations, product approvals, and concentration limits.
Can sodium fluoride and triclosan be combined in a new toothpaste?
The ingredients can be formulated together technically, but a new product would need to satisfy applicable FDA, local regulatory, labeling, safety, efficacy, and manufacturing requirements.
Does sodium fluoride have stronger patent protection than triclosan?
No. Both ingredients are longstanding actives. Commercial protection historically came from formulation combinations, delivery systems, clinical evidence, and brands rather than from new basic patents on either active ingredient.
Is Colgate Total still a triclosan product?
In the United States, Colgate Total was reformulated with stannous fluoride. The current active ingredients and availability can vary by country and product version.
Which fluoride technology replaced triclosan?
Stannous fluoride became the principal replacement in premium products because it supports cavity, gingivitis, sensitivity, and other oral-health claims without relying on triclosan.
References
-
U.S. Food and Drug Administration. (1997). Approval history and labeling for Colgate Total toothpaste, NDA 21-649. FDA Drugs@FDA.
-
U.S. Food and Drug Administration. (2016). Safety and effectiveness of consumer antiseptic washes; final rule. Federal Register, 81 Fed. Reg. 61106.
-
U.S. Food and Drug Administration. (2019). Approval history and labeling for Colgate Total SF toothpaste. FDA Drugs@FDA.
-
U.S. Food and Drug Administration. (2024). 21 C.F.R. Part 355: Anticaries drug products for over-the-counter human use. Electronic Code of Federal Regulations.
-
Colgate-Palmolive Company. (2024). Annual report for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
European Commission, Scientific Committee on Consumer Safety. (2010). Opinion on triclosan: Antimicrobial resistance and environmental effects. European Commission.
-
U.S. Patent and Trademark Office. (2024). Patent term and expiration information. U.S. Department of Commerce.
